Characterization of novel entecavir resistance mutations

Journal of Hepatology

Volumn 63, Issue 3, 2015, Pages 546-553

  Hayashi, Sanae ^a   Murakami, Shuko ^a   Omagari, Katsumi ^a   Matsui, Takeshi ^a,b   Iio, Etsuko ^a   Isogawa, Masanori ^a   Watanabe, Tsunamasa ^a   Karino, Yoshiyasu ^c   Tanaka, Yasuhito ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b TEINE KEIJINKAI HOSPITAL   (Japan)

^c Sapporo Kosei General Hospital   (Japan)

Author keywords

Antiviral resistance; Combination therapy; Entecavir; Entecavir resistance; HBV mutations; Hepatitis B treatment; Hepatitis B virus; Lamivudine; rtA186T; rtI163V; Viral breakthrough

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; ANTIVIRUS AGENT; GUANINE; RNA DIRECTED DNA POLYMERASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; BINDING AFFINITY; CASE REPORT; CHRONIC HEPATITIS B; CONTROLLED STUDY; DNA REPLICATION; DRUG EFFICACY; HEPATITIS B VIRUS; HUMAN; MOLECULAR MODEL; MONOTHERAPY; MOUSE; MUTAGENESIS; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; SIMULATION; VIRUS MUTATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL STRUCTURE; GENETICS; HEPATITIS B, CHRONIC; MUTATION;

ADULT; ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B, CHRONIC; HUMANS; MICE; MODELS, MOLECULAR; MUTATION; RNA-DIRECTED DNA POLYMERASE;

EID: 84939255104     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.03.020     Document Type: Article

References (31)

1. A.S. Lok Navigating the maze of hepatitis B treatments Gastroenterology 132 2007 1586 1594 10.1053/j.gastro.2007.02.040
2. Z.-L. Song, Y.-J. Cui, W.-P. Zheng, D.-H. Teng, and H. Zheng Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues World J Gastroenterol 18 2012 7149 7157 10.3748/wjg.v18.i48.7149
3. P. Karayiannis Direct acting antivirals for the treatment of chronic viral hepatitis Scientifica 2012 2012 478631 10.6064/2012/478631
4. L. Menéndez-Arias, M. Alvarez, and B. Pacheco Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance Curr Opin Virol 8C 2014 1 9 10.1016/j.coviro.2014.04.005
5. R.J. Colonno, R. Rose, C.J. Baldick, S. Levine, K. Pokornowski, C.F. Yu, and et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B Hepatology 44 2006 1656 1665 10.1002/hep.21422
6. D.J. Tenney, R.E. Rose, C.J. Baldick, K.A. Pokornowski, B.J. Eggers, J. Fang, and et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514 10.1002/hep.22841
7. S.F. Innaimo, M. Seifer, G.S. Bisacchi, D.N. Standring, R. Zahler, and R.J. Colonno Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus Antimicrob Agents Chemother 41 1997 1444 1448
8. M. Seifer, R.K. Hamatake, R.J. Colonno, and D.N. Standring In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir Antimicrob Agents Chemother 42 1998 3200 3208
9. M. Mukaide, Y. Tanaka, T. Shin-I, M.-F. Yuen, F. Kurbanov, O. Yokosuka, and et al. Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation Antimicrob Agents Chemother 54 2010 882 889 10.1128/AAC.01061-09
10. D.J. Tenney, S.M. Levine, R.E. Rose, A.W. Walsh, S.P. Weinheimer, L. Discotto, and et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine Antimicrob Agents Chemother 48 2004 3498 3507 10.1128/AAC.48.9.3498-3507.2004
11. Y. Tanaka, I. Hasegawa, T. Kato, E. Orito, N. Hirashima, S.K. Acharya, and et al. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D Hepatology 40 2004 747 755 10.1002/hep.20365
12. M. Sugiyama, Y. Tanaka, T. Kato, E. Orito, K. Ito, S.K. Acharya, and et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens Hepatology 44 2006 915 924 10.1002/hep.21345
13. T. Kimura, N. Ohno, N. Terada, A. Rokuhara, A. Matsumoto, S. Yagi, and et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain J Biol Chem 280 2005 21713 21719 10.1074/jbc.M501564200
14. F. Sugauchi, M. Mizokami, E. Orito, T. Ohno, H. Kato, S. Suzuki, and et al. A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: complete genome sequence and phylogenetic relatedness J Gen Virol 82 2001 883 892
15. K. Tatematsu, Y. Tanaka, F. Kurbanov, F. Sugauchi, S. Mano, T. Maeshiro, and et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J Virol 83 2009 10538 10547 10.1128/JVI.00462-09
16. M. Sugiyama, Y. Tanaka, F. Kurbanov, I. Maruyama, T. Shimada, S. Takahashi, and et al. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes Gastroenterology 136 2009 e3 10.1053/j.gastro.2008.10.048
17. C. Tateno, Y. Yoshizane, N. Saito, M. Kataoka, R. Utoh, C. Yamasaki, and et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs Am J Pathol 165 2004 901 912 10.1016/S0002-9440(10)63352-4
18. K. Morikami, T. Nakai, A. Kidera, M. Saito, and H. Nakamura Presto(protein engineering simulator): A vectorized molecular mechanics program for biopolymers Comput Chem 16 1992 243 248 10.1016/0097-8485(92)80010-W
19. W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, and M.L. Klein Comparison of simple potential functions for simulating liquid water J Chem Phys 79 1983 926 935
20. K. Omagari, D. Mitomo, S. Kubota, H. Nakamura, and Y. Fukunishi A method to enhance the hit ratio by a combination of structure-based drug screening and ligand-based screening Adv Appl Bioinforma Chem 2008 19 28
21. Y. Fukunishi, Y. Mikami, and H. Nakamura Similarities among receptor pockets and among compounds: analysis and application to in silico ligand screening J Mol Graph Model 24 2005 34 45 10.1016/j.jmgm.2005.04.004
22. S. Locarnini, and W.S. Mason Cellular and virological mechanisms of HBV drug resistance J Hepatol 44 2006 422 431 10.1016/j.jhep.2005.11.036
23. D.J. Tenney, S.M. Levine, R.E. Rose, A.W. Walsh, S.P. Weinheimer, L. Discotto, and et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine Antimicrob Agents Chemother 48 2004 3498 3507 10.1128/AAC.48.9.3498-3507.2004
24. M.-N. Brunelle, A.-C. Jacquard, C. Pichoud, D. Durantel, S. Carrouée-Durantel, J.-P. Villeneuve, and et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir Hepatology 41 2005 1391 1398 10.1002/hep.20723
25. S. Villet, A. Ollivet, C. Pichoud, L. Barraud, J.-P. Villeneuve, C. Trépo, and et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient J Hepatol 46 2007 531 538 10.1016/j.jhep.2006.11.016
26. S. Amini-Bavil-Olyaee, U. Herbers, T. Luedde, C. Trautwein, and F. Tacke Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains J Viral Hepat 18 2011 804 814 10.1111/j.1365-2893.2010.01378.x
27. D.R. Langley, A.W. Walsh, C.J. Baldick, B.J. Eggers, R.E. Rose, S.M. Levine, and et al. Inhibition of hepatitis B virus polymerase by entecavir J Virol 81 2007 3992 4001 10.1128/JVI.02395-06
28. M.N. Brunelle, J. Lucifora, J. Neyts, S. Villet, A. Holy, C. Trepo, and et al. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants Antimicrob Agents Chemother 51 2007 2240 2243 10.1128/AAC.01440-06
29. A.W. Walsh, D.R. Langley, R.J. Colonno, and D.J. Tenney Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir PLoS One 5 2010 e9195 10.1371/journal.pone.0009195
30. H. Yatsuji, N. Hiraga, N. Mori, T. Hatakeyama, M. Tsuge, M. Imamura, and et al. Successful treatment of an entecavir-resistant hepatitis B virus variant J Med Virol 2007 1811 1817 10.1002/jmv.20981
31. W.E.D. Iv, H. Yang, C.E. Westland, K. Das, E. Arnold, C.S. Gibbs, and et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication In Vitro 77 2003 11833 11841 10.1128/JVI.77.21.11833